Chapter 2.4 102 References 1. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9. 2. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95. 3. van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 2005;21:1163-71. 4. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen HL, de Man RA, Schalm SW. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4. 5. ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, Hansen BE, Haagmans BL, de Man RA, Schalm SW, Janssen HL. Patterns of viral decline during PEGinterferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006;44:721-7. 6. Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, Janssen HL. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 2005;54:1604-9. 7. Hansen BE, Buster EH, Steyerberg EW, Lesaffre E, Janssen HL. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol 2010;82:1135-42. 8. Mauryama NT, F. Takeuchi M. Prediction of an outcome using trajectories estimated from a linear mixed model. Journal of Biopharmaceutical Statistics 2009;19:779-790. 9. Brant LJ, Sheng SL, Morrell CH, Verbeke GN, Lesaffre E, Carter HB. Screening for prostate cancer by using random-effects models. Journal of the Royal Statistical Society Series A - Statistics in Society 2003;166(part 1):51-62. 10. Morrell CH, Brant LJ, Sheng S. Comparing approaches for predicting prostate cancer from longitudinal data, In Proceedings of the American Statistical Association, Alexandria, American Statistica Association, 2007. 11. Steyerberg EW. Clinical Prediction Models. Springer, 2009. 12. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11:561-70.
Dynamic prediction of response using longitudinal profi les 103 13. Buster EH, Hansen BE, Zeuzem S, Schalm SW, Steyerberg EW, Janssen HL. Predicting sustained hepatitis B virus eAg loss after treatement with peginterferon alpha-2b: development and validation of a pratical model European Journal of Gastroenterology & Hepatology Jul, 2008;20:A69-A70. 14. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009;137:2002-9. 15. Fieuws S, Verbeke G, Maes B, Vanrenterghem Y. Predicting renal graft failure using multivariate longitudinal profi les. Biostatistics 2008;9:419-31. 16. Fieuws S, Verbeke G, Brant LJ. Classifi cation of longitudinale profi les using nonlinear mixedeffects models.Technical report 0356. IAP Statistics Network. 17. Komárek A, Hansen BE, Kuiper EM, van Buuren HR, Lesaffre E. Discriminant analysis using a multivariate linear mixed model with a normal mixture in the random effects distribution. Statistics in Medicine 2010;in press. 18. Brant LJ, Sheng SL, Morrell CH, Zonderman AB. Data from a longitudinal study provided measurements of cognition to screen for Alzheimer’s disease. J Clin Epidemiol 2005;58:701-7. Acknowledgement The authors would like to thank Marek Molas, department of Biostatistics, <strong>Erasmus</strong> MC, <strong>Rotterdam</strong> , the Netherlands who wrote the SAS program for the adjustment of the predictions in the direct approach using the pattern approach. Foundation for Liver Research (SLO), <strong>Rotterdam</strong>, The Netherlands (HBV9901), Ministry of Education, Youth and Sports of the Czech Republic (MSM 0021620839), Czech Science Foundation (GAČR 201/09/P077), Belgian State – Federal Office for Scientific, Technical and Cultural Affairs (Interuniversity Attraction Poles Program P6/03).